ScripRakuten Aspyrian Inc. has raised $150m in Series C venture capital to fund a Phase III clinical trial that it intends to start before the end of this year to test its laser-activated antibody conjuga
ScripAnaBios Brings In $10m Series B Round, Including $4.2m From Principia AnaBios Corp. (focused on pain and cardiovascular and neurodegenerative diseases) closed a $10m Series B round, which included